Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (NorTick_EM)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Tick borne diseases are increasing in Norway. Lyme borreliosis is the most common infection. Erythema migrans is mainly diagnosed and treated in general practice. There is disagreement about what antibiotic treatment that should be given. An RCT with the three most common antibiotics used, will support data for revision of national guidelines.
| Condition | Intervention | Phase |
|---|---|---|
|
Erythema Migrans Erythema Chronicum Migrans Borreliosis Lyme Disease Early Lyme Disease |
Drug: Doxycycline Drug: Phenoxymethylpenicillin Drug: Amoxicillin |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline. |
- Duration of Erythema migrans (EM) [ Time Frame: 1-90 days ] [ Designated as safety issue: No ]On day 1 duration until first the consulation is registered. Day 1-14 the EM is registered in a patient diary. On day 14 the doctor is asked whether the EM has disseapeared. If not the patient is followed by phone from the researchers. On day 90 they are additionally asked for how long it lasted.
- Subjective Health Complaints (SHC) [ Time Frame: 1 year ] [ Designated as safety issue: No ]By questionnaire on day 1, day 90 and day 360 the patients are asked about their SHC which is a standardized set of parametres. The 3 treatment groups are compaired to each other and to 1200 healthy blood donors receiving the same questionnaire. There are 29 standardized and 3 Lyme disease related subjects to be measured.
- Borrelia antibodies [ Time Frame: 1-90 days ] [ Designated as safety issue: No ]Normally antibody production is not measured for EM as it is a clinical diagnosis, and less than 50 percent of EM-patients are expected to develop antibodies in the first period. However antibodies are here measured on day 1, day 14 and day 90 to see whether there are differences between the groups. Also the results will be compared to the blood donors.
- Side symptoms [ Time Frame: 1-14 days ] [ Designated as safety issue: Yes ]
The EM in it self is often asymptomatic, and fever, headache and nerval palsy can be a sign of disseminated disease or co-infection. On the quiestionnaire to the pasient and doctor on day 1, in the patient diary day 1-14 and on the questionnaire to the doctor on day 14 these side symptoms are registered.
In a potential case, where it turns out that the patient suffers from disseminated disease this will be regostered as treatment failure in the study and the patient treated and/or referred as normal.
- Side effects [ Time Frame: 1-14 days ] [ Designated as safety issue: No ]The antibiotic tretments are expected to be non-inferior to each other. Potensial side effects as nausea, diarrhea etc. are registered in the patients diary day 1-14 and in the doctors quiestionnaire on day 14.
- Subgrouping and TBE [ Time Frame: 1-14 days ] [ Designated as safety issue: No ]For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgroupring of the Borrelia bacteria. TBE-antibodies are measured on day 14.
| Estimated Enrollment: | 225 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Doxycycline
Doxycycline, 100 mg, tablets, b.i.d., 14 days
|
Drug: Doxycycline
1 tablet, 100 mg, b.i.d. 14 days
Other Name: Doksycycline 100 mg HEXAL, no. 30
|
|
Active Comparator: Penicillin
Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
|
Drug: Phenoxymethylpenicillin
Tablet 650 mg, 2 tablets, t.i.d., 14 days
Other Name: Weifapenin 650 mg, WEIFA, no. 100
|
|
Active Comparator: Amoxicillin
Amoxicillin 500 mg capsula, t.i.d., 14 days
|
Drug: Amoxicillin
Capsula, 500 mg, t.i.d., 14 days
Other Name: Amoxicillin 500 mg MYLAN, no. 30 + 20.
|
Detailed Description:
Comparison of phenoxymethylpenicillin, doxycycline and amoxicillin for Erythema migrans in Norwegian general practice. Every patient receives 14 days of antibiotic treatment. There are blood samples for measurement of Borrelia antibody level at day 1, 14 and 90 and questionnaires on subjective health complaints (SHC) at day 1, 90 and 360. Side symptoms and side effects are registered. For volunteers there is an additional PCR-analysis on punch biopsy from the EM for subgrouping of the Borrelia bacteria. TBE-antibodies are measured on day 14. Antibody levels and SHC-scores are compared to healthy blood donors.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of Erythema migrans
- Over the age of 18
- Signing an concent form after information in writing
Exclusion Criteria:
- Allergic to any of the three drugs in the study
- Under the age of 18
- Pregnancy
- Dementia or known drug abuse
- Antibiotic treatment last 14 days
- Concommitant Chemotherapy or immunomodulating therapy
- Concommitant use of medicine with potential interaction (defined in protocol)
Contacts and Locations| Contact: Knut Eirik Eliassen, MD | (+47) 97869609 | k.e.eliassen@medisin.uio.no |
| Contact: Siri E Janssen, Advisor | (+47)22850671 | s.e.janssen@medisin.uio.no |
| Norway | |
| Antibiotic Centre for Primary Care, University of Oslo | Recruiting |
| Oslo, Norway, 0318 | |
| Principal Investigator: Morten Lindbak, Dr med | |
| Principal Investigator: | Morten Lindbak, Professor | University of Oslo |
More Information
Additional Information:
No publications provided
| Responsible Party: | Professor Morten Lindbak, Antibiotic Centre for Primary Care, University of Oslo |
| ClinicalTrials.gov Identifier: | NCT01368341 History of Changes |
| Other Study ID Numbers: | EUDRACT 2010-023747 |
| Study First Received: | June 6, 2011 |
| Last Updated: | June 6, 2011 |
| Health Authority: | Norway: Norwegian Medicines Agency |
Keywords provided by University of Oslo:
|
Antibiotics General Practice Erythema migrans Borrelia Ticks |
Additional relevant MeSH terms:
|
Glossitis, Benign Migratory Borrelia Infections Erythema Chronicum Migrans Lyme Disease Erythema Tick-Borne Diseases Gram-Negative Bacterial Infections Bacterial Infections Spirochaetales Infections Skin Diseases, Bacterial Skin Diseases, Infectious Infection Skin Diseases Glossitis Tongue Diseases |
Mouth Diseases Stomatognathic Diseases Arbovirus Infections Virus Diseases Protozoan Infections Parasitic Diseases Amoxicillin Anti-Bacterial Agents Doxycycline Doxycycline hyclate Penicillin V Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antimalarials |
ClinicalTrials.gov processed this record on May 16, 2013